In vitro effects of 2-methoxyestradiol-bis-sulphamate on the non-tumorigenic MCF-12A cell line

Cell Biochemistry and Function

Volumn 28, Issue 5, 2010, Pages 412-419

  Johan Vorster, Christiaan Jacob ^a   Joubert, Anna Margaretha ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

2 methoxyestradiol; 2 methoxyestradiol bis sulphamate; Aapoptosis; Autophagy; Cancer

Indexed keywords

2 METHOXYESTRADIOL BIS SULPHAMATE; ANTINEOPLASTIC AGENT; CYCLIN B1; SULFUR DERIVATIVE; UNCLASSIFIED DRUG; 2-METHOXYESTRADIOL-3,17-O,O-BIS(SULFAMATE); ESTRANE DERIVATIVE;

ARTICLE; BREAST CELL; BREAST EPITHELIUM; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CELL DENSITY; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN MCF 12A; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG SCREENING; EPITHELIUM CELL; FLOW CYTOMETRY; IN VITRO STUDY; MITOSIS; PRIORITY JOURNAL; ULTRASTRUCTURE; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CHEMISTRY; FEMALE; HUMAN; METABOLISM; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN B1; ESTRENES; FEMALE; FLOW CYTOMETRY; G2 PHASE; HUMANS; TIME FACTORS;

EID: 77956863614     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1671     Document Type: Article

References (20)

1. Sutherland T, Anderson R, Hughes R, et al., 2-Methoxyestradiol - a unique blend of activities generating a new class of anti-tumour/antiinflammatory agents. Drug Discov Today 2007; 12: 577-584.
2. Mueck A, Seeger H, Huober J. Chemotherapy of breast cancer-additive anticancerogenic effects by 2-methoxyestradiol? Life Sci 2004; 75: 1205-1210.
3. Day J, Newman S, Comninos A, et al., The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 2003; 84: 317-325.
4. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato R. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997; 57: 81-86.
5. Ireson C, Chander S, Purohit A, et al., Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 2004; 90: 932-937.
6. James J, Murry D, Treston A, et al., Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2006; 25: 41-48.
7. Chander S, Foster P, Leese M, et al., In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br J Cancer 2007; 96: 1368-1376.
8. Mooberry S. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 2003; 6: 355-361.
9. Mooberry S. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 2003; 15: 425-430.
10. Bàrdos J, Ashcroft M. Negative and positive regulation of HIF-1: A complex network. Biochim Biophys Acta 2005; 1755: 107-120.
11. Hait W, Rubin E, Alli E, Goodin S. Tubulin targeting agents. Updat Cancer Ther 2007; 2: 1-18.
12. Ho Y, Newman S, Purohit A, Leese M, Potter B, Reed M. The effects of 2-methoxy oestrogens and their sulphamoylated derivatives in conjunction with TNF-alpha on endothelial and fibroblast cell growth, morphology and apoptosis. J Steroid Biochem Mol Biol 2003; 86: 189-196.
13. Strimpakos A, Karapanagiotou E, Saif M, Syrigos K. The role of mTOR in the management of solid tumors: An overview. Cancer Treat Rev 2009; 35: 148-159.
14. Raobaikady B, Purohit A, Chander S, et al., Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003; 84: 351-358.
15. Foster P, Ho Y, Newman S, et al., 2-MeOE2bisMATE and 2-EtE2bis- MATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res Treat 2008; 111: 251-260.
16. Purohit A, Vernon K, Wagenaar Hummelinck A, et al., The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 1998; 64: 269-275.
17. Suzuki R, Newman S, Purohit A, Leese M, Potter B, Reed M. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol- bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003; 84: 269-278.
18. Utsumi T, Leese M, Chander S, et al., The effects of 2-methoxyoestrogen sulphamates on the in vitro and in vivo proliferation of breast cancer cells. J Steroid Biochem Mol Biol 2005; 94: 219-227.
19. Hayat MA. The production of artifacts. Ultrastruct Pathol 1981; 2: 93.
20. 2 checkpoint through cyclin B1. Proc Natl Acad Sci USA 1999; 96: 2147-2152.